Puma Biotechnology Inc (PBYI) (Q2 2026) Earnings Call Highlights: Debt-Free Status and Raised …

This article first appeared on GuruFocus.

• Total Revenue: $56.5 million in Q2 2026.

• Product Revenue, Net: $53.6 million, up from $42 million in Q1 2026 and $49.2 million in Q2 2025.

• Royalty Revenue: $2.9 million in Q2 2026, compared to $2.8 million in Q1 2026 and $3.2 million in Q2 2025.

• Net Income (GAAP): $8.2 million, or $0.16 per diluted share, versus a net loss of $3.8 million in Q1 2026.

• Net Income (Non-GAAP): $10.1 million, or $0.20 per basic share and $0.19 per diluted share.

• Gross Revenue from NERLYNX Sales: $74.3 million in Q2 2026, up from $57.5 million in Q1 2026.

• Gross to Net Adjustment: 27.9% in Q2 2026, compared to 27% in Q1 2026.

• Cost of Sales: $12.5 million in Q2 2026, including $2.4 million for amortization of intangible assets.

• SG&A Expenses: $17.5 million in Q2 2026, down from $18.4 million in Q1 2026.

• R&D Expenses: $18.9 million in Q2 2026, down from $19.8 million in Q1 2026.

• Cash Burn: Approximately $9.7 million in Q2 2026, compared to cash generated of approximately $4 million in Q1.

• Cash Position: $93.9 million in cash, cash equivalents, and marketable securities as of June 30, 2026.

• NERLYNX Bottles Sold (Ex-Factory): 2,929 bottles in Q2 2026, a 26% increase quarter over quarter and 12% increase year over year.

• U.S. Demand: 2,986 bottles in Q2 2026, an 8% increase quarter over quarter and 11% increase year over year.

• Total Prescriptions (TRx): Increased 7% quarter over quarter and 3% year over year.

• New Prescriptions: Down approximately 6% compared to Q1 2026.

• FY 2026 Net Product Revenue Guidance: Raised to $205 million to $209 million.

• FY 2026 Royalty Guidance: $19 million to $22 million.

• FY 2026 Net Income Guidance: Raised to $17 million to $20 million.

Release Date: August 06, 2026

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Puma Biotechnology Inc (NASDAQ:PBYI) reported a strong second quarter with net product revenue of $53.6 million, a 27.6% increase from Q1 2026 and a 9% increase year-over-year.

• The company achieved GAAP net income of $8.2 million in Q2 2026, a significant improvement from the net loss of $3.8 million in Q1 2026.

• Puma Biotechnology Inc (NASDAQ:PBYI) is now debt-free after making its final loan payment of $11.1 million, strengthening its financial position.

• The company raised its full-year 2026 net product revenue guidance to $205-$209 million and net income guidance to $17-$20 million, reflecting confidence in continued growth.

• U.S. demand for NERLYNX increased 8% quarter-over-quarter and 11% year-over-year, with total prescriptions up 7% quarter-over-quarter, indicating strong commercial execution.

• Puma Biotechnology Inc (NASDAQ:PBYI) is advancing its alisertib clinical program, with plans to initiate ALISCA-Lung2 in Q3 2026 and potential for Phase III trials in 2027.

Negative Points

• New prescriptions for NERLYNX declined 6% quarter-over-quarter in Q2 2026, suggesting a potential slowdown in patient starts.

• The gross-to-net adjustment increased to 27.9% in Q2 2026 from 27% in Q1 2026, driven by a higher Medicaid share of sales, which could pressure future margins.

• Royalty revenue guidance for 2026 was lowered to $19-$22 million from the prior range of $20-$23 million, partly due to potential generic competition in China.

• The company reported cash burn of approximately $9.7 million in Q2 2026, a reversal from the $4 million cash generated in Q1 2026.

• R&D expenses are expected to increase by 34%-37% year-over-year in 2026, which could strain profitability if clinical trials face delays or setbacks.

• Puma Biotechnology Inc (NASDAQ:PBYI) faces uncertainty regarding the potential reduction of royalty rates in China, which could occur in late 2026 or 2027.

Q & A Highlights

Q: Can you speak to the R&D spend trajectory as we look into 2027, given the ongoing trials and the planned start of ALISCA-Lung2?A: Alan Auerbach, CEO, stated that the company’s current projections support the ability to fund Phase III trials for both alisertib in hormone receptor-positive breast cancer and small cell lung cancer. He noted that while the trials may need to be staggered, they are completely achievable. As a debt-free and cash flow positive company, Puma is eager to start Phase III trials next year, assuming the data continues to hold up, while remaining committed to maintaining positive net income.

Q: Can you elaborate on the types of business development (BD) opportunities Puma is evaluating?A: Alan Auerbach, CEO, explained that Puma is looking at both commercial-stage and development-stage assets. On the commercial side, they seek assets that can fit into the existing organization to generate additional sales and cash. On the development side, they are open to unique oncology assets across various technologies, not limited to small molecules or specific cancer types, provided they can help patients and benefit shareholders.

Q: What were the key drivers behind the strong commercial performance in Q2 2026?A: Roger Storms, SVP of Sales, highlighted that U.S. demand increased 8% quarter-over-quarter and 11% year-over-year, driven by executional excellence and increased field accountability. Call activity increased 18% year-over-year, and the specialty distributor channel saw demand grow by 32% year-over-year, fueled by growth in group purchasing organizations and 340B purchasing.

Q: What is the current status of the ALISCA-Breast1 trial, and what are the next steps?A: Alan Auerbach, CEO, reported that based on feedback from key opinion leaders on interim data, the company is amending the protocol to continue enrollment only in the 40 mg and 50 mg dose groups. The amendment has been submitted to the FDA and EU authorities, with enrollment under the amended protocol expected to begin in Q3. Updated interim data, including longer-term follow-up, will be presented in Q4 2026.

Q: What is the progress update on the ALISCA-Lung1 trial and the planned ALISCA-Lung2 trial?A: Alan Auerbach, CEO, noted that ALISCA-Lung1 currently has 92 patients enrolled, with dosing increased to 70 mg BID. The company plans to initiate ALISCA-Lung2, which will test alisertib in combination with paclitaxel, in Q3. Additional interim data from ALISCA-Lung1 and initial data from ALISCA-Lung2 are anticipated in 2027.

Q: What is the company’s financial guidance for the full year 2026?A: Maximo Nougues, CFO, raised guidance for net NERLYNX product revenue to $205 million to $209 million, up from prior guidance of $202 million to $206 million. Net income guidance was also raised to $17 million to $20 million, up from $16 million to $19 million. Royalty revenue guidance was slightly lowered to $19 million to $22 million, and the gross-to-net adjustment is expected to be between 26.5% and 27.5%.

Q: Can you provide details on the company’s cash position and debt status?A: Maximo Nougues, CFO, confirmed that Puma made its final quarterly principal loan payment of $11.1 million to Athyrium in Q2 2026, making the company debt-free. As of June 30, 2026, the company had approximately $93.9 million in cash, cash equivalents, and marketable securities. Q2 2026 cash burn was approximately $9.7 million.

Q: What is the potential impact of tariffs on the company’s operations?A: Maximo Nougues, CFO, stated that the company does not currently believe tariffs will have a material impact on product cost or results of operations. Manufacturing product cost accounts for a mid to high single-digit percentage of total cost of goods sold. However, he noted that shifting policies are rapidly evolving and difficult to predict.

Q: What is the outlook for the China royalty rate reduction?A: Maximo Nougues, CFO, explained that under the sublicense agreement covering China, the royalty rate is subject to reduction when the market share of generic versions of NERLYNX reaches a specific threshold. While the company cannot predict the exact timing, it believes the threshold could be reached in late 2026 or 2027, potentially triggering a royalty rate reduction.

Q: What are the expectations for Q3 2026?A: Maximo Nougues, CFO, guided for Q3 2026 net product revenue in the range of $54 million to $56 million, royalty revenue of $2 million to $3 million, and a gross-to-net adjustment of approximately 26% to 27%. No license revenue is expected in Q3.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.